There will be 2 Febrile Neutropenia dedicated sessions at this year’s symposium:
Parallel Session - Febrile Neutropenia — New Concepts in the Use of Granulocyte Stimulating Factors
Friday, June 29
10:00-11:30h
Made possible with an unrestricted grant from TEVA
| Chairs: Jean Klastersky, Belgium, Tom Walsh, USA |
| Management of low risk patients with FN: implementation of guidelines for antimicrobial therapy, home care and use of G-CSF’s
A. Freifeld, USA |
|
Respective merits and indications of the short acting and long acting G-CSF’s
Tom Walsh, USA |
|
The Papaldo’s hypothesis: should the indications for G-CSF’s be expanded?
B. Rapoport, South Africa |
Proffered Papers:
Breakthrough Febrile Neutropenia and Associated Complications among Elderly Cancer Patients Receiving Adjuvant Chemotherapy With Primary G-CSF Prophylaxis
A. Chan, C.P. Lee, J. Chiang, R. Ng, Singapore
Incidence and Outcome of Neutropenic Fever (NF) in One Year and Validation of MASCC Score-Index. A Single Center Experience
E. Azkona, A. Muñoz, I. Rubio, A. Ruiz de Lobera, S. Carrera, A. Sancho, I. Marrodán, E.I. Gutiérrez, M. Arruti, G. López-Vivanco, Infection-Myelosuppression Study Group, Spain
Outcome of Severe Infections in Afebrile Neutropenic Cancer Patients
K. Strojnik, K. Mahkovic-Hergouth, M. Blas, B. Jezersek Novakovic, B. Seruga, Slovenia
Proffered Papers Session - Febrile Neutropenia
Friday, June 29
15:30-17:00
| Chairs: Jean Klastersky, Belgium; Bernardo Rapoport, South Africa |
| One Year of Biosimilar Filgrastim in Routine Clinical Practice
Maria Sofia Rosati, G. Baciarello, M.L. Basile, S. Zancla, E. Ranieri
|
| Balugrastim — A Long-Acting, Once-Per-Cycle, Fixed-Dose Filgrastim: Pharmocokinetics and Pharmacodynamics in Patients with Breast Cancer
L. Pukac, S. Barash, N. Avisar, K.H. Emmert, H. Allgaier, J. Bock, Udo Mueller, D. Shen
|
| Influence of Ciprofloxacin on Rates of Febrile Neutropenia in Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy for Breast Cancer
D. Boehm, K. Gesy, H. Pituley, R. Ekberg, F. Forbes, J. Kolbinson, G. Narasimhan
|
| A Randomized, Non-Inferiority Study of Balugrastim and Pegfilgrastim in Breast Cancer Patients Receiving Myelosuppressive Therapy
O. Gladkov, V. Moiseyenko, I.N. Bondarenko, Y. Shparyk, S. Barash, J.M. Herpst, Udo Mueller
|
|
Efficacy and Safety of Balugrastim Compared with Pegfilgrastim in Patients with Breast Cancer who are Receiving Chemotherapy
C. Volovat, O.A. Gladkov, I.M. Bondarenko, S. Barash, A. Buchner, N. Avisar, P. Bias, Udo Mueller
|
|
A Randomized, Double-Blind, Active Control, Multicenter, Dose Finding Study of Lipegfilgrastim in Breast Cancer Patients Receiving Myelosuppressive Therapy
A. Buchner, P. Bias, M. Kaufmann, Udo Mueller |
|
|